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Abstract—Several studies have shown that tumor growth is
highly dependent on the presence of a mature vascular net-
work, thus therapies that inhibit tumor-induced vasculariza-
tion mechanisms can play a crucial role in the fight against
cancer. In order to develop effective targeted therapies and
individualized treatments, we have to consider the type and
molecular background of vascularization mechanisms and the
stage of the disease. In this paper a hybrid cellular automaton
model of pathological angiogenesis is presented, that explicitly
describes the pathophysiological processes taking place during
tumor progression. By simulating tumor cell proliferation and
necrosis, the diffusion of proangiogenic factors and nutrients,
sprouting angiogenesis and alternative vascularization mecha-
nisms, the model is able to reproduce similar capillary networks
and characteristic structures compared to results obtained in
vivo.
I. INTRODUCTION
According to studies conducted by the World Health Or-
ganization, the incidence of cancer has increased from 12.7
million in 2008 to 14.1 million in 2012. This trend is expected
to continue, leading to an increase by about 70% worldwide
in just two decades, thanks to the continued growth and aging
of the population and the spread of risk factors [1].
Cancer is a collection of diseases that can affect most
tissue types of the human body, and each tumor type has
unique features and progression. Physiological processes con-
trolling cellular functions, like proliferation and apoptosis,
are disrupted in the tumor environment. For many decades,
intravenous cytotoxic chemotherapy, radiation therapy and in
some cases surgical oncology have been the most widely
used treatments for cancerous diseases. The idea of inhibiting
the signaling pathways of certain tumor-specific regulatory
factors instead of targeting the rapidly dividing cells led to
novel therapeutic approaches and the emergence of targeted
molecular therapies (TMTs) [2].
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A. Therapeutic Approaches
Modern therapeutic approaches for the treatment of ma-
lignant tumors can be divided into two main groups. The
first group consists of conventional therapies that aim to
completely or partially remove the tumor from the body. Other
conventional approaches, such as chemotherapy and radiation
therapy share the common feature of targeting rapidly dividing
cells. This results in serious side effects, since there are other
cell populations under continuous division in the human body
[3].
Over the past few decades, the number of alternative and
supplementary cancer treatments have increased significantly.
New families of targeted therapies, namely antiangiogenic and
antivascular therapies have become a component of clinical
treatment in the past few years, thanks to the high number of
studies in the field that allow for a better understanding of the
physiological background of tumor growth [4].
B. Antiangiogenic Therapy
Signaling pathways of proangiogenic factors are among the
most common targets of TMTs. Inhibition of the signaling
of epidermal growth factor (EGFR) or vascular endothelial
growth factor (VEGF) on any level can effectively block the
neovascularization processes accompanying solid tumor devel-
opment. TMTs have also expanded the range of possibilities
for individualized cancer treatments [2].
The growth of a tumor is highly dependent on the continu-
ous supply of oxygen, nutrients, and host-derived regulator
molecules. In order to cover the basic metabolic needs of
the cells, the tumor is forced to develop its own vascular
network by inducing angiogenesis [5]. Antiangiogenic therapy
is designed to inhibit this process by blocking the signaling
pathways of proangiogenic factor receptors, such as VEGF,
HER1 or HER2. The VEGF-VEGFR-2 appears to be one of
the most important signal transduction pathways involved in
tumor angiogenesis, which makes VEGF inhibition a promis-
ing therapeutic approach.
C. Model-Based Therapeutic Approaches
Several studies have investigated antiangiogenic therapies,
and showed that in many cases the overall effectiveness is
far behind expectations. Other studies stated that the main
cause of the decline in efficiency is the poorly chosen drug
administration strategy [6]. In order to design optimal dosage
protocols and individualized therapies, we need to develop
computational models that are able to simulate spatio-temporal
changes in the cancer cell population and its environment. An
individualized targeted molecular therapy can greatly improve
the quality of life for cancer patients, lower costs and increase
the effectiveness of the treatments.
A mathematical model comprising ordinary differential
equations may be able to simulate the temporal changes in the
population of tumor cells, but these systems often have a high
number of parameters that are very hard or even impossible
to measure in vivo and describing spatial interactions typically
leads to partial differential equations. This implies that we
need to consider taking other modelling approaches as well.
In the past three decades, multiple cellular automaton (CA)
models of tumor growth have been proposed [7], [8]. The
biggest advantage of this approach comes from the funda-
mental concept of the CA. Local connections between the
cells make CAs able to model spatial changes in the hetero-
geneous tumor cell population conveniently and are able to
simulate complex pattern formation processes with a relatively
low number of parameters. Hybrid CA models that include
continuous, time-dependent processes, such as the diffusion
of molecules over the discrete lattice, are able to combine the
advantages of both approaches. Several models aim to simulate
intracellular interactions for an accurate modelling of tumor
growth or vascular development but more realistic systems
combine these processes and apply a multiscale approach [9],
[10], [11], [12]. Despite the high number of CA models, there
is a noticeable lack of discrete modelling solutions for tumor
growth that include alternative vascularization mechanisms.
Our aim in this article is to formulate a probabilistic
CA based dynamical model able to describe angiogenesis
and vasculature-dependent tumor growth in a computationally
efficient way.
II. METHODS
In this section, the hybrid cellular automaton model is de-
scribed. A square lattice simulation framework is introduced,
which is capable of simulating the basic behaviors of the
tumor cell population including proliferation and necrosis,
different vascularization mechanisms, and the diffusion of
tumor angiogenic factors (TAF).
A. Simulating the Tumor Environment
The first step towards a physiologically accurate spatio-
temporal simulation of tumor growth is the basic description
of the tumor environment and the host tissue. The simplest, yet
adequately informative approach is to model the surrounding
tissue as a square grid. Each location on this grid represents a
fixed size area of the given tissue. In this approach the whole
system can be described using simple numerical matrices what
makes computations fast and easy to optimize. A possible
simple solution is to represent each of the four modules of
the simulation framework with a separate matrix containing
the states of the cells in each iteration. As a possibility for
achieving maximum efficiency, a single partitioned matrix can
be introduced, that can be accessed by different modules in
parallel.
B. Basic Structure of the Model
The simulation framework is composed of the following
four modules:
1. Tumor growth: With a given initial vascular network, a
small population of tumor cells is present in the beginning
of the simulation. For the aim of simplicity, we assume
that tumor cells can proliferate thanks to the nutrient
supply provided by adjacent blood vessels of the host
tissue. Cells can proliferate exclusively if the nutrient
concentration in the neighboring cell is high enough
which implies that the closest blood vessel is within the
diffusion distance (100µm [13])
2. TAF diffusion: The overpopulated area of the tumor leads
to hypoxia, that induces TAF production and the diffusion
of proangiogenic factors into the interstitial space.
3. Blood vessel evolution: At the same time the TAF re-
leasing tumor enters the vascular stage, where diffusing
angiogenic growth factors stimulate nearby blood vessels
to grow new branches towards the stimulus or remodel
the network.
4. Nutrient diffusion: Both the initially present and the
newly developed vascular network components contribute
to the survival and growth of the tumor cell population. A
particular section of a blood vessel can provide nutrient
supply for a given number of adjacent cells.
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Fig. 1. Relationship of algorithm modules: 1) Tumor growth 2) TAF diffusion
3) Blood vessel evolution 4) Nutrient diffusion
As Fig. 1 shows, the different modules of the model are
interconnected. As a response to a growth in the number
of tumor cells (1) the amount of available nutrient per grid
location (4) will decrease (thanks to the increased metabolic
needs in that grid cell), and TAF diffusion (2) begins. The
released TAF molecules (2) reaching the already existing
vasculature around the tumor induce angiogenic processes that
lead to an increase in the number of vascularized grid cells
(3). The evolving vasculature (3) provides more grid cells with
nutrients (4), leading to an increase in the number of tumor
cells (1) and a decreased secretion of TAF (2).
In the proposed model the cells may be in the following 4
states:
Extracellular matrix: If the given location on the 2-
dimensional grid does not contain any tumor cells or
a capillary, it is considered being extracellular matrix
(ECM). A grid cell containing ECM can turn into a tumor
cell or a capillary based on the states of its neighbors and
the amount of nutrients and TAF at the given location.
Living tumor cell: A grid cell can contain tumor cells that
are either living or necrotized. Basically, cells that are on
the periphery of the tumor are considered living.
Necrotized tumor cell: If the grid location contains tumor
cells, but it is surrounded by other tumor cells absorbing
nutrients, the given grid cell will become part of the
necrotic core of the tumor.
Blood vessel: A continuous network of blood vessels can
form based on the amount of TAF in the grid locations.
A cell containing a blood vessel provides nutrient supply
for its neighbors.
Each cell corresponds to a 20µm x 20µm area of the
modelled tissue. In each iteration, the state of a given cell
can change based on its current state and the state of its
neighbors. For the cellular automaton rules describing alterna-
tive vascularization mechanisms, one of the most commonly
used approaches, the von Neumann neighborhood was imple-
mented. The simple von Neumann neighborhood of a cell can
be described as the cell itself and the cells at a Manhattan
distance of 1. By extending this neighborhood to cells at a
Manhattan distance of 2, we can simulate network evolution
rules that are occurring at a larger spatial scale. Using the von
Neumann neighborhood makes computations straightforward
and allows for an easier extension to 3 dimensions.
Note that blood vessels and the tumor population is stored
separately, meaning that a location in the 2-dimensional space
can contain tumor cells and a blood vessels at the same time.
This approach seems more realistic than a configuration where
tumor population and blood vessels are represented as two
mutually exclusive states of a cell.
The model comprises a relatively low number of parameters
that need to be identified in order to run physiologically
accurate simulations. These include the amount of initially
available nutrients CN0 , which is related to the type of host
tissue or the size limit of the avascular tumor, which is a
function of the amount of available nutrients. Other parame-
ters, like the probabilities of CA rules Pi can determine the
likelihood of each vascularization mechanism, while changing
the value of the diffusion coefficient D influences the speed
of TAF diffusion.
C. Tumor Growth
In the simplest scenario (Fig. 2), the tumor itself can be
approximated as an irregular circular shape (a 2-dimensional
section of a spheroid tumor), where the inner part represents
the necrotic core of dead tumor cells, and the outer part
contains the proliferating cells [14].
Fig. 2. The complex geometry of the tumor projected on a square lattice.
In the proposed model, simulations produced complex tu-
mor morphologies (Fig. 3) thanks to the realistic, nutrient-
dependent nature of tumor cell proliferation.
Time evolution of the tumor cell population is described
using CA rules that can determine the current state of each cell
based on the previous states of the cell itself and its neighbors.
In case of tumor cell proliferation and necrosis, the amount of
nutrients at each adjacent cell is also considered.
Fig. 3. Avascular initial tumor cells (on the left) and a growing tumor
population with a necrotic tumor core (green) generated by the model (on
the right)
D. TAF Diffusion
The diffusion of molecules is continuous in both space and
time. The density fluctuation of a diffusing material in two
dimensions can be described by a partial differential equation
in the form:
∂φ(x, y, t)
∂t
= D
(
∂2φ(x, y, t)
∂x2
+
∂2φ(x, y, t)
∂y2
)
(1)
where φ(x, y, t) is the density of the diffusing material at
location (x, y), and time t, and D is the diffusion coefficient.
The equation for the simulations on a discrete 2-dimensional
square lattice can be derived by discretizing (1) using an
explicit or implicit method. The explicit discretization can be
written as:
Cn+1i,j = C
n
i,j +
Dx∆t
dx2
(
Cni−1,j − 2Cni,j + Cni+1,j
)
+
Dy∆t
dy2
(
Cni,j−1 − 2Cni,j + Cni,j+1
)
, (2)
where Cni,j denotes the density of the diffusing material at
location (i, j) in time step n. An explicit discretization means
that in each time step n the concentrations depend only on
the concentrations measured in the previous time step. An
implicit discretization on the other hand takes into account
the concentrations at adjacent cells from the same time step
when computing the amount of TAF at a given position. Even
though implicit discretizations, such as the Backward Time,
Centered Space method or the Crank-Nicolson scheme [15]
can give more accurate and stable approximations for the
original equation, the explicit solution is implemented in the
proposed model. Since the stability of the explicit method
described above is sufficient for the simulations and the grid
cells represent large tissue areas compared to the scale of the
diffusing angiogenic factors, there are no significant bene-
fits from implementing more accurate implicit discretization
schemes.
Behaviors of a TAF releasing tumor can be approximated
by using (2) and tumor cells as distinct sources of the diffusing
material.
Fig. 4. Diffusion of TAF molecules released by the hypoxic tumor cell
population after reaching the crtical size of a few mm3 (Dx = Dy =
2, timestep = 0.1). We can see that only living tumor cells release TAF
molecules.
Tumor cell populations were initially placed in an un-
vascularized area simulating the state when diffusion-limited
nutrient uptake covers the metabolic needs of the tumor. This
is the avascular phase where no tumor cells are angiogenic
and expansion of the tumor is restricted to a few mm3. A
state transition (referred to as angiogenic switch [16]) occurs
(Fig. 4), resulting in the release and diffusion of proangiogenic
factors (TAF).
E. Blood Vessel Evolution
In order to simulate the evolution of capillary networks
(Fig. 6) in the presence of an angiogenically active tumor cell
population, we need to consider the interactions between the
ECM and tumor cells (i.e. nutrient and TAF diffusion) and
interactions between the ECM and endothelial cells (i.e. TAF
diffusion).
Alternative Vascularization Mechanisms: Next to the funda-
mental process of endothelial sprouting, where new capillary
buds from pre-existing host tissue capillaries are formed, 5
alternative vascularization mechanisms have been discovered
in the past decades. These mechanisms in most cases take
place simultaneously and can share some molecular features.
Non-sprouting forms of angiogenesis include vessel co-option,
intussusceptive microvascular growth, glomeruloid angiogen-
esis, postnatal vasculogenesis and vasculogenic mimicry [17].
Fig. 5. Differences between normal (A) and tumor-induced (B) vascular
networks. Several bifurcations, loops, glomeruloid bodies and a chaotic
structure in general. (Reprinted from [18] with permission. Copyright 2011
James W. Baish et al.)
Each of these processes are expected to result in different
pathological features shown by Fig. 5. Alternative mechanisms
implemented in the proposed model are the following:
Vessel co-option: this process includes the invasion of host
tissue and pre-existing microvessels, allowing the cancer
cells to reach the surface of blood vessels [17].
Intussusceptive microvascular growth: refers to the inser-
tion of connective tissue pillars into the lumen of already
existing capillaries, resulting in the partitioning of the
vessel. This type of vascularization is much faster than
sprouting angiogenesis and does not primarily depend on
endothelial proliferation [17].
Glomeruloid angiogenesis: a relatively high number of
closely associated microvessels form glomeruloid bodies
that can be related to with aggressive tumor behavior and
a reduced rate of survival [17].
Fig. 6. Schematic representation of the initial vasculature (left) and the
generated tumor-vasculature (right)
F. Nutrient Diffusion
Even though in real life the diffusion of different nutrients
is a continuous time-dependent process, in the model it is
only a function of the distance from the nearest blood vessel.
This representation can sufficiently describe the dependence of
tumor growth on the distance from the nearest nutrient supply,
thus there is no need to integrate a continuous process.
In this approach, the amount of available nutrients at a given
location on the 2-dimensional grid is calculated using a 9× 9
kernel.
Fig. 7. Nutrition map of a tumor cell population and basic branching
capillaries.
Applying this kernel to the matrix containing the vascular
network, we can generate a nutrition map where the amount
of nutrients in a given position is calculated based on its
neighborhood. To simulate the nutrient consumption of the
tumor cells, a similarly constructed 5 × 5 kernel is used in
the model with negative values. This way the presence of a
tumor cell will decrease the amount of available nutrients in
its environment.
As Fig. 7 shows, the amount of available nutrients decreases
as the distance from the nearest vessel is increasing. Both
proliferation and necrosis of tumor cells depend on the amount
of available nutrients at the given location, therefore the state
transitions of grid cells containing the tumor population are
determined using the nutrition matrix.
G. Time and Size Scales
Choosing the right time and size scales is essential for
accurate simulation results. In order to achieve this, we need
to investigate all cell- and tissue-level behaviors that are
described in the model. Since the average capillary diameter
is around 5 − 10µm and one grid cell represents an area of
tissue, which can contain tumor cells and capillaries at the
same time, the size of the grid cells was chosen as 20 µm
by 20 µm. A number of studies investigated the diffusion of
oxygen in different tissues. Results show that if intercapillary
distances exceed 100−140µm, the supply of oxygen reaches
the minimal level resulting in hypoxia [13]. In the proposed
model we assume that the maximum distance from a capillary,
where nutrients can be found, is 5 grid cells (100µm).
In order to precisely determine the time scales of different
mechanisms, a series of high resolution in vivo images fol-
lowing the time-evolution of the tumor mass and the capillary
network is needed.
III. RESULTS
Simulations were run for 400 generations on a sqaure
grid of 150 × 150 cells. In each simulation, a predefined
vasculature was present in the environment of the tumor and a
small amount of nutrient was provided in each grid location,
simulating the limited source for diffusion uptake (Fig. 8).
Fig. 8. Growing avascular tumor mass with necrotic regions (generation: 95)
Fig. 9. The vascular tumor releases TAF and induces angiogenesis (genera-
tion: 125)
As Fig. 9 shows, when the tumor reaches the limitations
set by nutrient diffusion and the ellipsoidal configuration, a
necrotic core is formed. This induces the release of TAF by
the living hypoxic tumor cells. Proangiogenic factors force the
predefined vasculature to grow new branches and develop an
irregular capillary network. A relatively high number of new
Fig. 10. As the newly developed capillary network reaches the living tumor
cells (generation: 210), the phenomenon of vessel co-option can be observed.
sprouts, bifurcations, self loops, anastomoses and glomeruloid
bodies can be observed (Fig. 10), thanks to the over-balancing
of growth factors. These network structures are produced by
the vascularization mechanisms implemented in the model
(i.e., sprouting, intussusception and glomeruloid growth).
These characteristic features often make tumor-vasculature
redundant, meaning that a given area of the tissue is supplied
by several capillaries at the same time. This redundancy can be
considered as an important parameter of the tumor vasculature.
Notwithstanding that there is a sufficient nutrient supply,
due to the rapid growth in the number of tumor cells, new
necrotic areas are emerging, leading to the resumption of
TAF production and vasculature development (Fig. 11). This
dynamic equilibrium is characteristic to the vascular stage of
tumor progression.
IV. CONCLUSION
In order to develop effective targeted therapies, we have to
consider the type of vascularization mechanisms, the molecu-
lar background and the stage of the disease.
Despite the simplicity of the model, results show that it
is able to reproduce tumor-specific network features (Fig.
5) and provide a detailed description of the spatio-temporal
distribution of tumor cells and blood vessels by incorporating
alternative vascularization mechanisms.
After the validation of the CA model, which in the first step
means a qualitative comparison with in vivo observations, the
simulations of cell-level interactions can be used to estimate
specific parameters of the tumor-vasculature for later use in
a previously built, concentrated parameter model of tumor
growth [19]. In addition to this, the model also provides
opportunities for simple extensions such as antiangiogenic
drug administration and 3-dimensional simulations.
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Fig. 11. Number of living and necrotized tumor cells and capillaries.
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